Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine-Reference-Cited by-同舟云学术

Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine

Published:2020-11-01 Issue:11 Volume:19 Page:995-1010
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

de Los Santos Abiel Mascareñas¹,Rodríguez-Weber Miguel Angel²,Sánchez-Márquez Pedro²,Traskine Magali³,Carreño-Manjarrez Roberto⁴^ORCID,Cervantes-Apolinar María Yolanda⁴,Strezova Ana³,Ruiz-Guiñazú Javier³⁵^ORCID,Ortega-Barria Eduardo⁶,Borys Dorota³^ORCID

Affiliation:

1. Universidad Autónoma De Nuevo León, Nuevo León, México

2. Instituto Nacional De Pediatría, Mexico D.F., Mexico

3. Vaccines, GSK, Wavre, Belgium

4. Vaccines, GSK, Mexico D.F., Mexico

5. Vaccines, Janssen Pharmaceutica, Beerse, Belgium

6. Vaccines, GSK, Panama City, Panama

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2020.1843431

Reference39 articles.

1. Cohen O, Knoll M, O’Brien K, et al. Pneumococcal Conjugate Vaccine (PCV) Product Assessment. 2017. [Cited 2019 Mar 4]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf

2. World Health Organization. Pneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME): summary of Findings from Systematic Review. October 2017 [Cited 2019 Feb 25]. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf?ua=1

3. The history of pneumococcal conjugate vaccine development: dose selection

4. Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial;The Lancet Infectious Diseases;2023-08

2. Breakthrough of glycobiology in the 21st century;Frontiers in Immunology;2023-01-05

3. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials;The Lancet Infectious Diseases;2022-09

4. Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus–Exposed Uninfected Infants: A Randomized Clinical Trial;Clinical Infectious Diseases;2022-01-17